巨核细胞发育和血小板产生的相关因素
中文名称
通路描述
巨核细胞(MKs)通过巨核细胞的终末分化产生循环血小板(血栓细胞),释放细胞质片段作为循环血小板。随着 MK 成熟,它们经历端粒复制(多倍体化)和细胞质质量的扩张,细胞大小超过 50-100 微米, ploidy 范围高达 128 N。随着 MK 成熟,多倍核呈马蹄形,细胞质扩张,血小板细胞器和分界膜系统被放大。形成血小板突起,产生新的循环血小板(Deutsch & Tomer 2006)。
巨核细胞分化和血小板产生过程发生在复杂的微环境中,其中趋化因子、细胞因子和粘附相互作用发挥主要作用(Avecilla et al. 2004)。巨核细胞分化和血小板产生在几个水平上受到调节,包括增殖、分化和血小板释放(Kaushansky 2003)。血小板生成素(TPO/c-Mpl 配体)是最强促增殖和巨核细胞成熟的细胞因子(Kaushansky 2005),但许多其他生长因子也参与其中。MK 发育由多种转录因子的作用控制。许多 MK 特异性基因由 GATA 和 friend of GATA(FOG)、RUNX1 和 ETS 蛋白共同调节。核因子 erythroid 2(NF-E2),具有 MK-erythroid 特异性 45-kDa 亚基,控制终末 MK 成熟、血小板突起形成和血小板释放(Schulze & Shivdasani 2004)。NF-E2 缺陷小鼠具有严重的血小板减少症(Shiraga et al. 1999)。MYB(c-myb)与 EP300(p300)作为血小板生成的负调节因子发挥作用(Metcalf et al. 2005)。在 MK 成熟期间,内部膜系统、颗粒和细胞器被组装。细胞质碎片化需要 MK 细胞骨架的变化和细胞器及通道的形成。单个细胞器从细胞体迁移到血小板突起末端,在任意给定时间约有 30% 的细胞器/颗粒处于运动状态(Richardson et al. 2005)。
巨核细胞分化和血小板产生过程发生在复杂的微环境中,其中趋化因子、细胞因子和粘附相互作用发挥主要作用(Avecilla et al. 2004)。巨核细胞分化和血小板产生在几个水平上受到调节,包括增殖、分化和血小板释放(Kaushansky 2003)。血小板生成素(TPO/c-Mpl 配体)是最强促增殖和巨核细胞成熟的细胞因子(Kaushansky 2005),但许多其他生长因子也参与其中。MK 发育由多种转录因子的作用控制。许多 MK 特异性基因由 GATA 和 friend of GATA(FOG)、RUNX1 和 ETS 蛋白共同调节。核因子 erythroid 2(NF-E2),具有 MK-erythroid 特异性 45-kDa 亚基,控制终末 MK 成熟、血小板突起形成和血小板释放(Schulze & Shivdasani 2004)。NF-E2 缺陷小鼠具有严重的血小板减少症(Shiraga et al. 1999)。MYB(c-myb)与 EP300(p300)作为血小板生成的负调节因子发挥作用(Metcalf et al. 2005)。在 MK 成熟期间,内部膜系统、颗粒和细胞器被组装。细胞质碎片化需要 MK 细胞骨架的变化和细胞器及通道的形成。单个细胞器从细胞体迁移到血小板突起末端,在任意给定时间约有 30% 的细胞器/颗粒处于运动状态(Richardson et al. 2005)。
英文描述
Factors involved in megakaryocyte development and platelet production Megakaryocytes (MKs) give rise to circulating platelets (thrombocytes) through terminal differentiation of MKs which release cytoplasmic fragments as circulating platelets. As MKs mature they undergo endoreduplication (polyploidisation) and expansion of cytoplasmic mass to cell sizes larger than 50-100 microns, and ploidy ranges up to 128 N. As MKs mature, the polyploid nucleus becomes horseshoe-shaped, the cytoplasm expands, and platelet organelles and the demarcation membrane system are amplified. Proplatelet projections form which give rise to de novo circulating platelets (Deutsch & Tomer 2006).
The processes of megakaryocytopoiesis and platelet production occur within a complex microenvironment where chemokines, cytokines and adhesive interactions play major roles (Avecilla et al. 2004). Megakaryocytopoiesis is regulated at several levels including proliferation, differentiation and platelet release (Kaushansky 2003). Thrombopoietin (TPO/c-Mpl ligand) is the most potent cytokine stimulating proliferation and maturation of MK progenitors (Kaushansky 2005) but many other growth factors are involved. MK development is controlled by the action of multiple transcription factors. Many MK-specific genes are co-regulated by GATA and friend of GATA (FOG), RUNX1 and ETS proteins. Nuclear factor erythroid 2 (NF-E2), which has an MK-erythroid specific 45-kDa subunit, controls terminal MK maturation, proplatelet formation and platelet release (Schulze & Shivdasani 2004). NF-E2 deficient mice have profound thrombocytopenia (Shiraga et al. 1999). MYB (c-myb) functions with EP300 (p300) as a negative regulator of thrombopoiesis (Metcalf et al. 2005). During MK maturation, internal membrane systems, granules and organelles are assembled. Cytoplasmic fragmentation requires changes in the MK cytoskeleton and formation of organelles and channels. Individual organelles migrate from the cell body to the proplatelet ends, with approximately 30 percent of organelles/granules in motion at any given time (Richardson et al. 2005).
The processes of megakaryocytopoiesis and platelet production occur within a complex microenvironment where chemokines, cytokines and adhesive interactions play major roles (Avecilla et al. 2004). Megakaryocytopoiesis is regulated at several levels including proliferation, differentiation and platelet release (Kaushansky 2003). Thrombopoietin (TPO/c-Mpl ligand) is the most potent cytokine stimulating proliferation and maturation of MK progenitors (Kaushansky 2005) but many other growth factors are involved. MK development is controlled by the action of multiple transcription factors. Many MK-specific genes are co-regulated by GATA and friend of GATA (FOG), RUNX1 and ETS proteins. Nuclear factor erythroid 2 (NF-E2), which has an MK-erythroid specific 45-kDa subunit, controls terminal MK maturation, proplatelet formation and platelet release (Schulze & Shivdasani 2004). NF-E2 deficient mice have profound thrombocytopenia (Shiraga et al. 1999). MYB (c-myb) functions with EP300 (p300) as a negative regulator of thrombopoiesis (Metcalf et al. 2005). During MK maturation, internal membrane systems, granules and organelles are assembled. Cytoplasmic fragmentation requires changes in the MK cytoskeleton and formation of organelles and channels. Individual organelles migrate from the cell body to the proplatelet ends, with approximately 30 percent of organelles/granules in motion at any given time (Richardson et al. 2005).
所含基因
96 个基因
ABL1
ACTB
AK3
AKAP1
AKAP10
CABLES1
CABLES2
CAPZA1
CAPZA2
CAPZB
CBX5
CDC42
CDK2
CDK5
DOCK1
DOCK10
DOCK11
DOCK2
DOCK3
DOCK4
DOCK5
DOCK6
DOCK7
DOCK8
DOCK9
EHD1
EHD2
EHD3
GATA1
GATA2
GATA3
GATA4
GATA5
GATA6
H3F3A
HBB
HBD
HBE1
HBG1
HBG2
HDAC1
HDAC2
HIST1H3A
HIST2H3A
HMG20B
IFNA1
IFNA10
IFNA14
IFNA16
IFNA17
IFNA2
IFNA21
IFNA4
IFNA5
IFNA6
IFNA7
IFNA8
IFNB1
IRF1
IRF2
ITPK1
JAK2
JMJD1C
KDM1A
LRRC16A
MAFF
MAFG
MAFK
MFN1
MFN2
MICAL1
MYB
NFE2
PHF21A
PRKACA
PRKACB
PRKACG
PRKAR1A
PRKAR1B
PRKAR2A
PRKAR2B
RAB5A
RAC1
RAD51B
RAD51C
RCOR1
SH2B1
SH2B2
SH2B3
SIN3A
TP53
VPS45
WEE1
ZFPM1
ZFPM2
ZFYVE20